These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18844587)

  • 1. IC51: a new investigational Japanese encephalitis vaccine. Dr Christoph Klade speaks to Duc Le, editor.
    Klade CS
    Expert Rev Vaccines; 2008 Oct; 7(8):1139-40. PubMed ID: 18844587
    [No Abstract]   [Full Text] [Related]  

  • 2. IC51 Japanese encephalitis vaccine.
    Kollaritsch H; Paulke-Korinek M; Dubischar-Kastner K
    Expert Opin Biol Ther; 2009 Jul; 9(7):921-31. PubMed ID: 19527110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixiaro: a new vaccine against Japanese encephalitis.
    Jelinek T
    Expert Rev Vaccines; 2009 Nov; 8(11):1501-11. PubMed ID: 19863241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese encephalitis: update on vaccines and vaccine recommendations.
    Wilder-Smith A; Halstead SB
    Curr Opin Infect Dis; 2010 Oct; 23(5):426-31. PubMed ID: 20581670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.
    Tauber E; Kollaritsch H; von Sonnenburg F; Lademann M; Jilma B; Firbas C; Jelinek T; Beckett C; Knobloch J; McBride WJ; Schuller E; Kaltenböck A; Sun W; Lyons A
    J Infect Dis; 2008 Aug; 198(4):493-9. PubMed ID: 18588481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.
    Schuller E; Klade CS; Wölfl G; Kaltenböck A; Dewasthaly S; Tauber E
    Vaccine; 2009 Mar; 27(15):2188-93. PubMed ID: 19200452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.
    Eder S; Dubischar-Kastner K; Firbas C; Jelinek T; Jilma B; Kaltenboeck A; Knappik M; Kollaritsch H; Kundi M; Paulke-Korinek M; Schuller E; Klade CS
    Vaccine; 2011 Mar; 29(14):2607-12. PubMed ID: 21288804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chimeric live attenuated vaccine against Japanese encephalitis.
    Jones T
    Expert Rev Vaccines; 2004 Jun; 3(3):243-8. PubMed ID: 15176941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.
    Kaltenböck A; Dubischar-Kastner K; Eder G; Jilg W; Klade C; Kollaritsch H; Paulke-Korinek M; von Sonnenburg F; Spruth M; Tauber E; Wiedermann U; Schuller E
    Vaccine; 2009 Jul; 27(33):4483-9. PubMed ID: 19486955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new inactivated Japanese encephalitis vaccine for adult travelers.
    Toovey S
    Travel Med Infect Dis; 2009 Sep; 7(5):301-4. PubMed ID: 19747666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Japanese encephalitis: is there a need for a novel vaccine?
    Wilder-Smith A; Freedman DO
    Expert Rev Vaccines; 2009 Aug; 8(8):969-72. PubMed ID: 19627179
    [No Abstract]   [Full Text] [Related]  

  • 12. A new Japanese encephalitis vaccine (Ixiaro).
    Med Lett Drugs Ther; 2009 Aug; 51(1319):66-7. PubMed ID: 19696707
    [No Abstract]   [Full Text] [Related]  

  • 13. Japanese encephalitis vaccine for travelers: exploring the limits of risk.
    Shlim DR; Solomon T
    Clin Infect Dis; 2002 Jul; 35(2):183-8. PubMed ID: 12087525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese encephalitis vaccine in travelers.
    Jelinek T
    Expert Rev Vaccines; 2008 Jul; 7(5):689-93. PubMed ID: 18564023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert opinion on vaccination of travelers against Japanese encephalitis.
    Teitelbaum P
    J Travel Med; 2009; 16(6):441; author reply 441-2. PubMed ID: 19930391
    [No Abstract]   [Full Text] [Related]  

  • 16. [Japanese encephalitis].
    Jelinek T
    Dtsch Med Wochenschr; 2002 May; 127(21):1155-6. PubMed ID: 12085312
    [No Abstract]   [Full Text] [Related]  

  • 17. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.
    Lyons A; Kanesa-thasan N; Kuschner RA; Eckels KH; Putnak R; Sun W; Burge R; Towle AC; Wilson P; Tauber E; Vaughn DW
    Vaccine; 2007 Apr; 25(17):3445-53. PubMed ID: 17241714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yellow fever and Japanese encephalitis vaccines: indications and complications.
    Marfin AA; Eidex RS; Kozarsky PE; Cetron MS
    Infect Dis Clin North Am; 2005 Mar; 19(1):151-68, ix. PubMed ID: 15701552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.
    Jones T
    Curr Opin Mol Ther; 2009 Feb; 11(1):90-6. PubMed ID: 19169964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.
    Schuller E; Jilma B; Voicu V; Golor G; Kollaritsch H; Kaltenböck A; Klade C; Tauber E
    Vaccine; 2008 Aug; 26(34):4382-6. PubMed ID: 18599165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.